Prucalopride improves bowel function and colonic transit time in patients with chronic constipation: an integrated analysis.

ABSTRACT:

Objectives

Constipation is often characterized by slow colonic transit, but the relationship between colonic transit time (CTT) and symptoms is unclear. The aims of this study were to investigate the effect of prucalopride, a 5-hydroxytryptamine receptor-4 agonist, on CTT and assess the relationship between CTT and symptoms.

Methods

This was an integrated analysis of three randomized, placebo-controlled, phase 2 dose-finding trials of prucalopride in patients with chronic constipation (ClinicalTrials.gov identifiers: NCT00617513; NCT00631813; and NCT00596596). Measurements of CTT were analyzed using radio-opaque markers at the start and end (4 or 12 weeks) of treatment. At these visits, patients assessed the presence and severity of their symptoms.

Results

In total, 2

SUBMITTER: Emmanuel A 

PROVIDER: S-EPMC4050523 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature